BIOMAT Database Logo BIOMAT Database Logo

Plasma somatostatin-like immunoreactivity during growth-hormone-releasing hormone therapy in non-growth-hormone-deficient children. 1990

E Arilla, and J Fragoso, and R Barrio, and B Colás, and S Donnay, and B Roca, and M Hernández
Departamento de Bioquímica y Biologia Molecular, Facultad de Medicina, Universidad de Alcalá de Henares, España.

To date, the effects of long-term growth hormone (GH)-releasing hormone [GHRH(1-29)-NH2] treatment on the plasma concentrations of somatostatin-like immunoreactivity (SLI) remain undefined. In the present study, the effect of GHRH(1-29)-NH2 therapy on plasma SLI levels has been studied in 11 non-GH-deficient children. The pattern of administration was 5 micrograms/kg body weight, given subcutaneously once every day. There was no significant change in plasma SLI levels after bolus injection of GHRH(1-29)-NH2 before and during GHRH(1-29)-NH2 therapy. However, plasma SLI rose in basal plasma and nocturnal sleep after 3 months of GHRH(1-29)-NH2 therapy and remained the same during 6 months of treatment with GHRH(1-29)-NH2. The reason for this finding is uncertain, but an increase in SLI release from the enteroinsular axis is a possible explanation. The association of our findings with the role of the circulating SLI on nutrient homeostasis and the effects of GNRH on growth velocity is discussed.

UI MeSH Term Description Entries
D007279 Injections, Subcutaneous Forceful administration under the skin of liquid medication, nutrient, or other fluid through a hollow needle piercing the skin. Subcutaneous Injections,Injection, Subcutaneous,Subcutaneous Injection
D011863 Radioimmunoassay Classic quantitative assay for detection of antigen-antibody reactions using a radioactively labeled substance (radioligand) either directly or indirectly to measure the binding of the unlabeled substance to a specific antibody or other receptor system. Non-immunogenic substances (e.g., haptens) can be measured if coupled to larger carrier proteins (e.g., bovine gamma-globulin or human serum albumin) capable of inducing antibody formation. Radioimmunoassays
D001827 Body Height The distance from the sole to the crown of the head with body standing on a flat surface and fully extended. Body Heights,Height, Body,Heights, Body
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D006130 Growth Disorders Deviations from the average values for a specific age and sex in any or all of the following: height, weight, skeletal proportions, osseous development, or maturation of features. Included here are both acceleration and retardation of growth. Stunted Growth,Stunting,Disorder, Growth,Growth Disorder,Growth, Stunted,Stuntings
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013004 Somatostatin A 14-amino acid peptide named for its ability to inhibit pituitary GROWTH HORMONE release, also called somatotropin release-inhibiting factor. It is expressed in the central and peripheral nervous systems, the gut, and other organs. SRIF can also inhibit the release of THYROID-STIMULATING HORMONE; PROLACTIN; INSULIN; and GLUCAGON besides acting as a neurotransmitter and neuromodulator. In a number of species including humans, there is an additional form of somatostatin, SRIF-28 with a 14-amino acid extension at the N-terminal. Cyclic Somatostatin,Somatostatin-14,Somatotropin Release-Inhibiting Hormone,SRIH-14,Somatofalk,Somatostatin, Cyclic,Somatotropin Release-Inhibiting Factor,Stilamin,Somatostatin 14,Somatotropin Release Inhibiting Factor,Somatotropin Release Inhibiting Hormone
D013007 Growth Hormone-Releasing Hormone A peptide of 44 amino acids in most species that stimulates the release and synthesis of GROWTH HORMONE. GHRF (or GRF) is synthesized by neurons in the ARCUATE NUCLEUS of the HYPOTHALAMUS. After being released into the pituitary portal circulation, GHRF stimulates GH release by the SOMATOTROPHS in the PITUITARY GLAND. Growth Hormone-Releasing Factor,Somatocrinin,Somatotropin-Releasing Factor 44,Somatotropin-Releasing Hormone,GHRH 1-44,GRF 1-44,Growth Hormone-Releasing Factor 44,Human Pancreatic Growth Hormone-Releasing Factor,Somatoliberin,hpGRF 44,Growth Hormone Releasing Factor,Growth Hormone Releasing Factor 44,Growth Hormone Releasing Hormone,Somatotropin Releasing Factor 44,Somatotropin Releasing Hormone
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor

Related Publications

E Arilla, and J Fragoso, and R Barrio, and B Colás, and S Donnay, and B Roca, and M Hernández
Circulating somatomedin-C levels and the effect of growth hormone-releasing factor on plasma levels of growth hormone and somatostatin-like immunoreactivity in obese children.
January 1987, European journal of pediatrics,
E Arilla, and J Fragoso, and R Barrio, and B Colás, and S Donnay, and B Roca, and M Hernández
Subcutaneous growth hormone-releasing hormone therapy in growth hormone-deficient children: first year of therapy.
October 1992, The Journal of clinical endocrinology and metabolism,
E Arilla, and J Fragoso, and R Barrio, and B Colás, and S Donnay, and B Roca, and M Hernández
Defective response of plasma growth hormone to growth hormone releasing factor in growth hormone deficient children.
January 1992, Zhonghua Minguo xiao er ke yi xue hui za zhi [Journal]. Zhonghua Minguo xiao er ke yi xue hui,
E Arilla, and J Fragoso, and R Barrio, and B Colás, and S Donnay, and B Roca, and M Hernández
Human growth hormone therapy of non-growth hormone deficient children.
January 1987, Pediatrician,
E Arilla, and J Fragoso, and R Barrio, and B Colás, and S Donnay, and B Roca, and M Hernández
Changes in plasma FGF23 in growth hormone deficient children during rhGH therapy.
January 2011, Journal of pediatric endocrinology & metabolism : JPEM,
E Arilla, and J Fragoso, and R Barrio, and B Colás, and S Donnay, and B Roca, and M Hernández
Growth hormone releasing factor-like immunoreactivity in human milk.
March 1986, Biochemical and biophysical research communications,
E Arilla, and J Fragoso, and R Barrio, and B Colás, and S Donnay, and B Roca, and M Hernández
Increase in bone density and plasma osteocalcin during growth hormone therapy in growth hormone deficient children.
January 1997, Journal of pediatric endocrinology & metabolism : JPEM,
E Arilla, and J Fragoso, and R Barrio, and B Colás, and S Donnay, and B Roca, and M Hernández
Somatostatin-like immunoreactivity in duck plasma, hypothalamus and neural lobe during post-hatch growth: comparison with plasma and pituitary growth hormone concentrations.
April 1987, The Journal of endocrinology,
E Arilla, and J Fragoso, and R Barrio, and B Colás, and S Donnay, and B Roca, and M Hernández
Distribution of growth hormone-releasing hormone-like immunoreactivity in human tissue extracts.
August 1984, The Journal of clinical endocrinology and metabolism,
E Arilla, and J Fragoso, and R Barrio, and B Colás, and S Donnay, and B Roca, and M Hernández
Plasma levels of growth hormone-releasing hormone and somatostatin in response to a mixed meal and during sleep in children.
December 1987, Acta endocrinologica,
Copied contents to your clipboard!